Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Machine, Furnitures, Fixtures & OtherOther Gross PP&E Adjustments
Ratios

Spyre Therapeutics (SYRE) Leases (2019 - 2023)

Spyre Therapeutics (SYRE) has disclosed Leases for 5 consecutive years, with $2.3 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Leases fell 35.93% year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Jun 2023, down 35.93%, and an annual FY2022 reading of $3.4 million, up 329.82% over the prior year.
  • Leases was $2.3 million for Q2 2023 at Spyre Therapeutics, down from $3.3 million in the prior quarter.
  • Across five years, Leases topped out at $4.9 million in Q3 2019 and bottomed at $68000.0 in Q4 2020.
  • Average Leases over 5 years is $3.1 million, with a median of $3.7 million recorded in 2022.
  • Peak annual rise in Leases hit 6410.0% in 2020, while the deepest fall reached 98.56% in 2020.
  • Year by year, Leases stood at $4.7 million in 2019, then crashed by 98.56% to $68000.0 in 2020, then surged by 1073.53% to $798000.0 in 2021, then soared by 329.82% to $3.4 million in 2022, then tumbled by 32.48% to $2.3 million in 2023.
  • Business Quant data shows Leases for SYRE at $2.3 million in Q2 2023, $3.3 million in Q1 2023, and $3.4 million in Q4 2022.